Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
Remember Nat R. bought 60,000 shares at over £4 a couple of years ago, so even then he saw value, we’ve moved up a few gears since so every chance you’ll get your wish !
“Everything Alistar said can now be disregarded” ….you mean this as well in his last dying breath ..“ Avacta has been able to leverage this excellent progress in the clinic to progress conversations with potential commercial partners “. I think many are now left wondering who to believe, it certainly ain’t the Chairman !
Disappointed AS has been ousted, CC turns the language down and DX to go. Just hope CC ‘s business skills match her scientific ones. Meanwhile the CFO and Chairman ( don’t worry about funding ) escape….hmm, not impressed. Shall now review my investment here.
Interesting article in the Times today, about Zandy Forbes, the eccentric CEO of MeiraGTx, another promising UK biotech. Her comments resonate here;
“Would she have floated on the LSE, if she had her time again? Absolutely not, she says. Small biotechs are risky, “money-burning endeavours,” she says. Meira, for example, invests in developing new medicines, but does not sell any treatments to patients yet.
While US pension funds and hedge funds have spent two decades gaining expertise in how to evaluate and invest in such drug developers, UK investors are simply not prepared to fund those risks.”
And as we’ve found out !
PL. Many companies get away with Placings at much thinner discounts to the prevailing SP, why because their perceived risk factors are much lower, ours clearly aren’t in the eyes of those approached for funding support who will have studied all availability Data.. Professional investors are merely cold and calculated, unlike most retail investors who buy and suddenly fall in love with the stock, often losing substantial capital thus would be more appropriate to describe them as ‘clueless ‘. Witness the level of passion on this BB when finding AS has strung them along yet again, or heaven forbid someone has gone Short !
And that’s the continuing conundrum, the recent Placing that will have involved many with knowledge in this field,
haven’t shown the same enthusiasm towards the emerging data. Guess many bear the scars of previous CT’s that haven’t quite lived up to expectations!
Are you sure they weren’t referring to the Moderna/MSD trials involving vaccine mRNA-4157 (V940), being the world’s first personalised mRNA cancer jab for melanoma, and likely other cancers, which is still in trials. Just highlights we need to get a move on !
Naturally we all talk from an Investors perspective, many working to develop new areas of science their motivation can be quite different. AS doesn’t strike me as someone who’s only interested in financial gain thus this vehicle we’re in may not hold the resale valve some expect !